Vertex: More Appealing At A Lower Price, But Don't Rush In (Rating Upgrade)
Vertex Software faces strong competition and slower growth, leading to a neutral rating. See why VERX stock remains pricey ...
Vertex Pharmaceuticals says VX-264 study did not meet primary endpoint
Vertex Pharmaceuticals (VRTX) announced several updates on the company’s type 1 diabetes portfolio. Vertex has completed enrollment and dosing ...
Netflix, Vertex Pharmaceuticals And More On CNBC's 'Final Trades'
On CNBC's “Halftime Report Final Trades ,” Jim Lebenthal of Cerity Partners said he is long-term bullish but a bit nervous ...
Zacks Investment Research on MSN3d
Vertex Pharmaceuticals (VRTX) Advances While Market Declines: Some Information for Investors
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $502.55, marking a +0.45% move from the previous day. The stock's change was more than the S&P 500's daily loss of 0.33%. At the ...
Zacks Investment Research on MSN4d
Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock
Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...
Vertex: Expectations Reset With Improved Fundamentals (Rating Upgrade)
Vertex's cloud growth momentum remains strong, with a 27% y/y increase in 4Q24. Read more to see why I upgrade VERX stock ...
Investing Snacks5d
Painfully Profitable: Vertex’s Shot Beyond CF
Vertex Pharmaceuticals is flexing its innovation muscles beyond its cystic fibrosis stronghold, charging into new territories ...